T-CELL MALIGNANCIES
Clinical trials for T-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new T-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for T-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 17, 2026 02:16 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR-T cells for people with T-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to better attack the cancer. The tri…
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD5-CAR T cells for people with T-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own or a donor's immune cells, which are modified in a lab to better attack the cancer. The goal is to f…
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New hope for rare blood cancers: experimental drug ELA026 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called ELA026 in adults with T/NK cell cancers that have come back or not responded to prior treatments. The main goals are to check safety and find the right dose. About 84 participants will take part across multiple centers.
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC